Enhanced p62 expression triggers concomitant autophagy and apoptosis in a rat chronic spinal cord compression model

Molecular Medicine Reports

Volumn 9, Issue 6, 2014, Pages 2091-2096

  Chen, Zhi ^a   Fu, Qingge ^b   Shen, Baoliang ^c   Huang, Xuan ^a   Wang, Kun ^a   He, Ping ^a   Li, Fengning ^a   Zhang, Fan ^a   Shen, Hongxing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Shanghai Jiading Central Hospital   (China)

Author keywords

Cell apoptosis; Cell autophagy; Chronic spinal cord compression model; p62

Indexed keywords

CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P62; HEAT SHOCK PROTEIN; SQSTM1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL SURVIVAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; LOCOMOTION; NERVE DEGENERATION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RAT; SPINAL CORD COMPRESSION; SPINAL CORD INJURY; ANIMAL; ANTERIOR HORN CELL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ANTERIOR HORN CELLS; APOPTOSIS; AUTOPHAGY; CASPASE 3; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HEAT-SHOCK PROTEINS; NF-KAPPA B; RATS; SPINAL CORD COMPRESSION;

EID: 84899676491     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2124     Document Type: Article

References (38)

1. Hayashi H, Okada K, Hamada M, Tada K and Ueno R: Etiologic factors of myelopathy. A radiographic evaluation of the aging changes in the cervical spine. Clin Orthop Relat Res: 200-209, 1987.
2. Ogino H, Tada K, Okada K, et al: Canal diameter, anteroposterior compression ratio, and spondylotic myelopathy of the cervical spine. Spine (Phila Pa 1976) 8: 1-15, 1983.
3. Edwards WC and LaRocca H: The developmental segmental sagittal diameter of the cervical spinal canal in patients with cervical spondylosis. Spine (Phila Pa 1976) 8: 20-27, 1983.
4. Ito T, Oyanagi K, Takahashi H, Takahashi HE and Ikuta F: Cervical spondylotic myelopathy. Clinicopathologic study on the progression pattern and thin myelinated fibers of the lesions of seven patients examined during complete autopsy. Spine (Phila Pa 1976) 21: 827-833, 1996.
5. Gooding MR, Wilson CB and Hoff JT: Experimental cervical myelopathy. Effects of ischemia and compression of the canine cervical spinal cord. J Neurosurg 43: 9-17, 1975.
6. Hukuda S and Wilson CB: Experimental cervical myelopathy: effects of compression and ischemia on the canine cervical cord. J Neurosurg 37: 631-652, 1972.
7. Long HQ, Li GS, Hu Y, Wen CY and Xie WH: HIF-1alpha/VEGF signaling pathway may play a dual role in secondary pathogenesis of cervical myelopathy. Med Hypotheses 79: 82-84, 2012.
8. Fehlings MG and Skaf G: A review of the pathophysiology of cervical spondylotic myelopathy with insights for potential novel mechanisms drawn from traumatic spinal cord injury. Spine (Phila Pa 1976) 23: 2730-2737, 1998.
9. Yu WR, Baptiste DC, Liu T, Odrobina E, Stanisz GJ and Fehlings MG: Molecular mechanisms of spinal cord dysfunction and cell death in the spinal hyperostotic mouse: implications for the pathophysiology of human cervical spondylotic myelopathy. Neurobiol Dis 33: 149-163, 2009.
10. Yu WR, Liu T, Kiehl TR and Fehlings MG: Human neuropathological and animal model evidence supporting a role for Fas-mediated apoptosis and inflammation in cervical spondylotic myelopathy. Brain 134: 1277-1292, 2011.
11. Kim DH, Vaccaro AR, Henderson FC and Benzel EC: Molecular biology of cervical myelopathy and spinal cord injury: role of oligodendrocyte apoptosis. Spine J 3: 510-519, 2003.
12. Karadimas SK, Gialeli CH, Klironomos G, et al: The role of oligodendrocytes in the molecular pathobiology and potential molecular treatment of cervical spondylotic myelopathy. Curr Med Chem 17: 1048-1058, 2010.
13. Hara T, Nakamura K, Matsui M, et al: Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441: 885-889, 2006.
14. Komatsu M, Waguri S, Chiba T, et al: Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441: 880-884, 2006.
15. Sarkar S, Ravikumar B, Floto RA and Rubinsztein DC: Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine- expanded huntingtin and related proteinopathies. Cell Death Differ 16: 46-56, 2009.
16. Pan T, Kondo S, Zhu W, Xie W, Jankovic J and Le W: Neuroprotection of rapamycin in lactacystin-induced neuro-degeneration via autophagy enhancement. Neurobiol Dis 32: 16-25, 2008.
17. Wong E and Cuervo AM: Autophagy gone awry in neuro-degenerative diseases. Nat Neurosci 13: 805-811, 2010.
18. Keane RW, Kraydieh S, Lotocki G, et al: Apoptotic and anti-apoptotic mechanisms following spinal cord injury. J Neuropathol Exp Neurol 60: 422-429, 2001.
19. Yoshino O, Matsuno H, Nakamura H, et al: The role of Fas-mediated apoptosis after traumatic spinal cord injury. Spine (Phila Pa 1976) 29: 1394-1404, 2004.
20. Casha S, Yu WR and Fehlings MG: FAS deficiency reduces apoptosis, spares axons and improves function after spinal cord injury. Exp Neurol 196: 390-400, 2005.
21. Erlich S, Alexandrovich A, Shohami E and Pinkas-Kramarski R: Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis 26: 86-93, 2007.
22. Sekiguchi A, Kanno H, Ozawa H, Yamaya S and Itoi E: Rapamycin promotes autophagy and reduces neural tissue damage and locomotor impairment after spinal cord injury in mice. J Neurotrauma 29: 946-956, 2012.
23. Duran A, Serrano M, Leitges M, et al: The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 6: 303-309, 2004.
24. Rodriguez A, Durán A, Selloum M, et al: Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab 3: 211-222, 2006.
25. Duran A, Linares JF, Galvez AS, et al: The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 13: 343-354, 2008.
26. Kuusisto E, Salminen A and Alafuzoff I: Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 12: 2085-2090, 2001.
27. Zatloukal K, Stumptner C, Fuchsbichler A, et al: p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 160: 255-263, 2002.
28. Nagaoka U, Kim K, Jana NR, et al: Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions. J Neurochem 91: 57-68, 2004.
29. Komatsu M, Waguri S, Koike M, et al: Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 131: 1149-1163, 2007.
30. Jin Z, Li Y, Pitti R, et al: Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137: 721-735, 2009.
31. Sanz L, Diaz-Meco MT, Nakano H and Moscat J: The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. EMBO J 19: 1576-1586, 2000.
32. Moscat J, Diaz-Meco MT, Albert A and Campuzano S: Cell signaling and function organized by PB1 domain interactions. Mol Cell 23: 631-640, 2006.
33. Moscat J and Diaz-Meco MT: p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 137: 1001-1004, 2009.
34. Xu P, Gong WM, Li Y, et al: Destructive pathological changes in the rat spinal cord due to chronic mechanical compression. Laboratory investigation. J Neurosurg Spine 8: 279-285, 2008.
35. Basso DM, Beattie MS and Bresnahan JC: A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 12: 1-21, 1995.
36. Kuusisto E, Kauppinen T and Alafuzoff I: Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathol Appl Neurobiol 34: 169-180, 2008.
37. Karin M and Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227, 2002.
38. Sheikh MS and Huang Y: Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle 2: 550-552, 2003.